ENSO

1.5 billion people worldwide live with chronic pain, and the best option they have are drugs like Vicodin that have terrible side effects and make people feel sick. ENSO has developed the first opioid-free, wearable device clinically proven to solve pain better than Vicodin. It works by delivering a patented electrical stimulation treatment that relaxes the muscles and calms the nerves wherever it is applied, and it's all controlled via an app on your smartphone. Enso is being used to solve chronic and acute pain at over 100 medical centers in the US such as Stanford, Harvard and Cedars-Sinai. The device is covered by the VA Hospitals and workers compensation insurance plans and is expected to be covered by major commercial insurance plans by 2021.

ENSO headquartered in United States, North America, operates in the Consumer, Medical Device, Wearables sector. The company focuses on Consumer and has secured $178.8M in funding across 24 round(s). With a team of 11-50 employees, ENSO is actively contributing to advancements in Consumer. Their latest funding round, Seed Round - ENSO, raised $2.9M. Discover more about their projects, partnerships, and impact on our platform.